Home>>Signaling Pathways>> Apoptosis>> APC>>Apcin

Apcin

Catalog No.GC18518

Apcin is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C).

Products are for research use only. Not for human use. We do not sell to patients.

Apcin Chemical Structure

Cas No.: 300815-04-7

Size Price Stock Qty
1mg
$26.00
In stock
5mg
$90.00
In stock
10mg
$144.00
In stock
25mg
$288.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apcin is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C). Apcin competitively binds to Cdc20 and prevents substrate interaction and ubiquitylation required for continuation of mitosis. Apcin enhances the effect of the APC/C inhibitor N-4-tosyl-L-arginine methyl ester and its prodrug, proTAME, leading to an increase in the number of cells in mitosis, a longer mitotic duration, and greater stabilization of cyclin B1, cycB1-NT, securin, and cyclin A2. Apcin, in combination with proTAME, synergistically increases apoptosis in multiple myeloma cells.

References:
[1]. Sackton, K.L., Dimova, N., Zeng, X., et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C Nature 514(7524), 646-649 (2014).
[2]. Lub, S., Maes, A., De Veirman, K., et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells Oncotarget 7(4), 4062-4076 (2016).

Reviews

Review for Apcin

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apcin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.